Allarity Therapeutics, Inc.

NasdaqCM ALLR

Allarity Therapeutics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -17,273.21%

Allarity Therapeutics, Inc. Net Income Margin is -17,273.21% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Allarity Therapeutics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -1,080.82%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: ALLR

Allarity Therapeutics, Inc.

CEO	Mr. Thomas H. Jensen
IPO Date	Dec. 21, 2021
Location	United States
Headquarters	210 Broadway
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years